| 引用本文: |
陈星,陈文,张璐莹.药品“基于绩效的风险分担协议”的国际经验与启示*[J].中国卫生经济,2023,42(9):90-92,96.[点击复制] |
Chen Xing,Chen Wen,Zhang Luying.International Experiences and Enlightenment of “Performance-Based Risk-Sharing Agreement” for Drug[J].CHINESE HEALTH ECONOMICS,2023,42(9):90-92,96.[点击复制] |
|
| 摘要: |
| 随着全球药品费用支出增长加剧，如何控制药品费用，确保居民及时获得所需药品成为各国卫生系统的重点之一。基于绩效的风险分担协议是降低创新药品不确定性，保障居民用药可及性和可负担性的合理工具。通过系统分析和比较澳大利亚、英国和意大利3个典型国家实施药品基于绩效的风险分担协议的背景、方式和效果，并从数据收集、协议制定、药品评估和信息公开等方面提出基于绩效的风险分担协议对我国实施药品政策的启示。 |
| 关键词: 药品 基于绩效的风险分担协议 国际经验 |
| DOI： |
| 投稿时间：2023-06-13 |
| 基金项目:国家社会科学基金重大项目 （20ZDA072） |
|
| International Experiences and Enlightenment of “Performance-Based Risk-Sharing Agreement” for Drug |
| Chen Xing,Chen Wen,Zhang Luying |
| (School of Public Health, Fudan University, Shanghai, 200032 , China) |
| Abstract: |
| As global spending on drugs increases, one of the priorities for national health systems is how to control the cost of drugs and ensure that residents get the drugs they need promptly. Performance-based risk-sharing agreement (PBRSA) is a reasonable tool to reduce uncertainty about innovative drug and to ensure access and affordability for the residents.Through systematically analyzes and compares the background, approach, and effect of implementing PBRSA for drugs in Australia, the UK. and Italy. In data collection, agreement development, drug evaluation and information disclosure, it proposea policy implications for implementing drug PBRSA in China. |
| Key words: drug performance-based risk-sharing agreement international experience |
